Innoveren Scientific (Innoveren Scientific) Change In Working Capital : $1.01 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Change In Working Capital?

Innoveren Scientific's change in working capital for the quarter that ended in Sep. 2023 was $0.16 Mil.

Innoveren Scientific's change in working capital for the fiscal year that ended in Dec. 2022 was $0.46 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Innoveren Scientific Change In Working Capital Historical Data

The historical data trend for Innoveren Scientific's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific Change In Working Capital Chart

Innoveren Scientific Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

1.72

-0.10

-0.19

-0.76

0.46

Innoveren Scientific Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Working Capital	Get a 7-Day Free Trial															0.23	0.40	0.15	0.31	0.16

Innoveren Scientific Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.01 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Innoveren Scientific Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Innoveren Scientific (Innoveren Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607

Website

https://www.hcyte.com

Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.

Executives

Fwhc Holdings, Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone	director	201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel	officer: Chief Financial Officer	201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif	officer: President and C.E.O.	19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc	10 percent owner	2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch	10 percent owner	C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc	10 percent owner	334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner	10 percent owner	3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky	director	2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne	director, officer: Chief Executive Officer	201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford	director	714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615